Women With AML Have Worse Outcomes With Gemtuzumab Ozogamicin
Combination gemtuzumab ozogamicin (GO) and cytarabine is no more effective than standard
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Combination gemtuzumab ozogamicin (GO) and cytarabine is no more effective than standard
Understanding Low Risk MDS 2021 Winter Patient Family Conference
Adrienne Phillips, MD, MPH
Understanding Aplastic Anemia 2021 Winter Patient Family Conference
Anna Koget, DO
Understanding Low Risk MDS 2021 Fall Patient Family Conference
Suresh Balasubramian, MD, Karmanos Cancer Center
Understanding Aplastic Anemia 2021 Fall Patient Family Conference
Daria Babushok, MD, PhD, Penn Medicine
Managing the Side Effects of Bone Marrow Failure - Summer 2021 Conference
Eric Padron, MD, Moffitt Cancer Center
Diagnosing Bone Marrow Failure Diseases - Summer 2021 Conference
Amy Duffield, MD, PhD, Memorial Sloan Kettering
8th Seattle Patient Conference: Ask an Expert
H. Joachim Deeg, MD
8th Seattle Patient Conference - Living Well with MDS/MPN
Krisstina Gowin, DO, University of Arizona
What Are My Options with High Risk MDS/AML: Spring 2021 Conference (Apr 2021)
Nathan Punwani, MD, Cedars-Sinai
What's My Mutation? Understanding the Risks for Low/Moderate Risk MDS Patients: Spring 2021 Conference (Apr 2021)
Tiffany Tanaka, MD, UC San Diego Health
This session will provide a comprehensive overview of high risk MDS and the transition to MDS, from diagnosis to treatment.
This session is suitable for patients, family members, and caregivers who are living with a diagnosis of higher risk MDS and who may (or already have) transition to AML. Dr.
